<DOC>
	<DOCNO>NCT01477476</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled phase 2 study . Specific aim evaluate feasibility safety anti-IL-1 ( interleukin 1 ) treatment course standard therapy diabetic ketoacidosis child effect intracranial pressure .</brief_summary>
	<brief_title>Anti-IL-1 Treatment Children Diabetic Keto-Acidosis ( DKA ) Diagnosis Type 1 Diabetes</brief_title>
	<detailed_description>Anakinra fully human IL-1ra ( interleukin 1 receptor agonist ) license 2001 FDA treatment rheumatoid arthritis . It competitively bind IL-1 receptor , thus block IL-1 signaling . It short-acting agent require daily subcutaneous administration 1-2 mg/kg , maximum 100 mg/dose . It effective lower HbA1c ( glycated haemoglobin ) T2D ( type 2 diabetes ) randomize trial anakinra recent onset T1D ( type 1 diabetes ) underway Europe . Overall , anakinra use adult child good safety record , 10 year . Infrequent side effect include infection , neutropenia , nausea , diarrhea , cardiopulmonary arrest , influenza-like symptom , production anti-anakinra antibody . Study Design : A double-blinded placebo-controlled RCT ( randomize control trial ) 2:1 allocation ( 14 active treatment vs. 7 placebo ) . Anakinra treatment give bolus 2 mg/kg infuse intravenously 30 minute follow infusion 2 mg/kg/hour 4 hour immediately confirmation diagnosis DKA ( diabetic keto-acidosis ) laboratory safety parameter available ( CBC ( complete blood count ) pregnancy test ) consent obtain . Primary outcome : Safety tolerability anti-IL-1 treatment ( anakinra ) initial 24 hr period DKA treatment . Secondary outcome : Optic nerve sheath diameter ( cut-off define cerebral edema : 4.5 mm ) ; Changes cytokine level treatment anakinra .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Acidosis</mesh_term>
	<mesh_term>Ketosis</mesh_term>
	<mesh_term>Diabetic Ketoacidosis</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Age 818 year diagnosis type 1 diabetes Diabetic ketoacidosis : plasma glucose concentration &gt; 300 mg/dl , venous pH &lt; 7.30 serum bicarbonate concentration &lt; 15 mmol/L , ketone urine serum Hematology : WBC &gt; 3000 x 109/L ; platelet &gt; 100,000 x 109/L ; hemoglobin &gt; 10.0 g/dL Negative blood pregnancy test female . Children underlie disorder , include : active autoimmune immune deficiency disorder type 1 diabetes , malignancy , organ transplant , condition require chronic corticosteroid use Previous immunotherapy prevent type 1 diabetes Current prior infection HIV , hepatitis B hepatitis C assess history Patients present DKA concomitant alcohol drug use , Head trauma , Meningitis condition might affect neurological function Renal failure Any condition , medical otherwise would , opinion investigator , prevent complete participation study , would pose significant hazard subject 's participation Patients history know hypersensitivity : E coliderived protein , anakinra , component investigational drug product</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>DKA</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Type I Diabetes</keyword>
</DOC>